BCL2 and acute myeloid leukemia: In conclusion, while BCL-2 inhibition with Ven is now commonly used for AML patients, our proposed combination of Ven and PegC is a novel, mechanistically-based regimen that is unique to the field and has the advantage of combining two drugs already in clinical use for acute leukemias, with use and potential toxicities familiar to oncologists.